Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
Ver/Abrir
Use este enlace para citar
http://hdl.handle.net/2183/21219Colecciones
- GI-FENM - Artigos [117]
Metadatos
Mostrar el registro completo del ítemTítulo
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapyFecha
2017-04-13Cita bibliográfica
Antón-Aparicio LM, Peláez Fernández I, Cassinello J. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol. 2017;19(10): 1175-1182
Resumen
[Abstract] The immune system regulates angiogenesis in cancer by way of both pro- and antiangiogenic activities. A bidirectional link between angiogenesis and the immune system has been clearly demonstrated. Most antiangiogenic molecules do not inhibit only VEGF signaling pathways but also other pathways which may affect immune system. Understanding of the role of these pathways in the regulation of immunosuppressive mechanisms by way of specific inhibitors is growing. Renal cell carcinoma (RCC) is an immunogenic tumor in which angiogenesis and immunosuppression work hand in hand, and its growth is associated with impaired antitumor immunity. Given the antitumor activity of selected TKIs in metastatic RCC (mRCC), it seems relevant to assess their effect on the immune system. The confirmation that TKIs improve cell cytokine response in mRCC provides a basis for the rational combination and sequential treatment of TKIs and immunotherapy.
Palabras clave
Tyrosine kinase inhibitors
Immunomodulation
Angiogenesis
Renal cell carcinoma
Immunotherapy
Immunomodulation
Angiogenesis
Renal cell carcinoma
Immunotherapy
Descripción
Review article
Versión del editor
ISSN
1699-048X